Bubs Australia Won Permanent US Access — Then Its Shares Jumped 45%
The FDA authorised three infant-formula products for permanent US marketing, replacing emergency-era uncertainty and opening a path to branded and private-label expansion.
What changed, why it matters, and what most people may be overlooking.
The FDA authorised three infant-formula products for permanent US marketing, replacing emergency-era uncertainty and opening a path to branded and private-label expansion.